Transaction · 0002124755-26-000007

Chin Peter Scott

Chin Peter Scott, CMO, reported an open-market or private sale at Denali Therapeutics Inc. involving 1654.000000 shares for an estimated $36867.66. Reported holdings after the transaction were 204538.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

Open-market sellSEC transaction code SCMO
DNLIDenali Therapeutics Inc.
Trade date
Sep 04, 2026
Filing date
Sep 09, 2026
View on SEC Insider profile
Estimated value-$36.8kShares × reported price
Shares traded1.65k$22.29 per share
Holdings after204kDirect
% of reported position traded0.8%This security and ownership context
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 206,192 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

DNLI price since this filing

Daily closing prices, with the filing date and available return windows
DNLI · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +13.2%1w ago +11.3%1d ago +5.7%
Returns since7d -7.0%30d -13.4%90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0002124755-26-000007
Common Stock
Transaction date
Sep 04, 2026
Filed Sep 09, 2026, 08:44 PM · 5d delay
Shares
1,654 sh
$22.29 per share
Estimated value
-$36.8k
Computed from shares × price
Holdings after
204,538 sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Cluster Selling Direct Ownership
Filing-only score

+6 points

Compact filing score computed from stored Form 4 facts. Version v1.

Positive filing signal

This filing has a modest positive filing-only score. Treat it as a useful flag for review, not as a buy signal.

How this score is calculated
  • direct_ownership+6 points

    direct_or_indirect_ownership = D

    Direct ownership reports the insider's personal stake.
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

Chief Medical Officer

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units.

  2. F2

    The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $22.28 to $22.29 per share. Upon request by the Commission staff, the Issuer, or a

  3. security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

  4. F3

    Includes 142,845 Unvested RSU's

  5. F4

    Includes 1,790 shares acquired under the ESPP Purchase on June 1, 2026.

Original filing · 0002124755-26-000007
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

DNLI